**WP11-NoE-Adolescent and Young adults with cancer**

**WP11 12-month update (October 2022 - September 2023)**

The endorsement criteria and identification of participants were defined as following:

1) Health care providers, comprehensive cancer centers:  The centers must have European scope (e.g. participation to EU projects/EU collaborative groups etc.)

* National leadership/mandate: centers need the capacity, capability and resources to participate at the European level in order to then lead/guide the implementation of recommendations of the NoE at the national level
* Specific competence/expertise on AYA proven by coordination/participation in national networks/programmes; AYA dedicated research/study; publication track on AYA with cancers
* Proven collaboration between paediatric and adult oncology
* Proven collaboration with national AYA programme/activities/associations

2) Scientific and professional societies/networks/research groups: The endorsement criteria must be the European scope (e.g. involved in EU projects on health care organization, public policy, clinical practice guidelines, etc.)

* Scientific societies (SIOPE, ESMO, EHA, EONS, ECO, ESTRO, ESSO, OECI)
* European Reference Networks (EURACAN, PaedCan, EuroBloodNet, Genturis)
* Research organization(EORTC, European Network of Cancer Registries)
* Collaborative groups AYA focused (ENTYAC)

3) Patient advocacy groups

The NoE must include patient and public involvement (PPI) groups as active members. The PPI is considered a key component of the whole project, to ensure that patients’ needs are really met, and each results leads to a real benefit for the patient. The major endorsement criteria remain the European scope. The NoE should involve Youth Cancer Europe, Childhood Cancer International (CCI) – Europe and European Cancer Patient Coalition (ECPC).